Why Autonomix Medical Stock Has More Than Doubled Today

Shares of Autonomix Medical, Inc. (NASDAQ: AMIX) more than doubled on Tuesday, as the small-cap medical device company rode a fresh wave of intellectual property news that reignited speculative buying interest.

The stock touched an intraday high of $7.76, up as much as 112% from Monday’s close of $3.65 in heavy trading of more than 44 million shares.

The rally was sparked by Autonomix’s announcement that the U.S. Patent and Trademark Office issued Patent No. 12,433,670, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.”

The patent covers technology for mapping nerves associated with tumors and cancer-related pain, further expanding the intellectual property moat around the company’s catheter-based neuromodulation platform. It marks the latest in a string of patent grants this summer for Autonomix, following IP awarded for overactive bladder treatment, renal denervation, and autonomic nervous system assessment tools.

Beyond the headline news, traders point to Autonomix’s unusually small float as an accelerant. After a 1-for-21 reverse stock split completed in late June, the company had fewer than one million shares outstanding as of late July, making the stock highly susceptible to sharp, volatile swings on relatively modest dollar volume.

The Woodlands, Texas-based company has seen wild price action for weeks, including a 66% surge in late July on no specific news and a 16% drop days later.

Autonomix remains a clinical-stage company; its nerve-sensing and ablation platform, aimed initially at pancreatic cancer pain with potential applications in hypertension and cardiology, has not yet received FDA marketing clearance.

As of late July, the company reported roughly $5.1 million in cash, underscoring that today’s move reflects speculative enthusiasm around intellectual property momentum rather than commercial revenue or regulatory approval.